| Authors: |
Zhang H; Precision Medicine, R&D, GSK, Waltham, Massachusetts., Rutkowska A; Cellzome, a GSK Company, R&D, GSK, Heidelberg, Germany., González-Martín A; Medical Oncology Department, Clínica Universidad de Navarra, Madrid, Spain.; Center for Applied Medical Research (CIMA), Pamplona, Spain.; Grupo Español de Investigación en Cáncer de Ovario (GEICO), Madrid, Spain., Mirza MR; Nordic Society of Gynaecological Oncology (NSGO) and Department of Oncology Rigshospitalet-Copenhagen University Hospital, Copenhagen, Denmark., Monk BJ; Florida Cancer Specialists and Research Institute, West Palm Beach, Florida., Vergote I; Gynecologic Oncology, Katholieke Universiteit Leuven, Leuven, Belgium., Pothuri B; Department of Obstetrics and Gynecology, NYU School of Medicine, New York City, New York., Graybill WAS; Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, South Carolina., Goessel C; Clinical Development, Oncology, GSK, Waltham, Massachusetts., Barbash O; Precision Medicine, GSK, Collegeville, Pennsylvania, Philadelphia., Bergamini G; Cellzome, a GSK Company, R&D, GSK, Heidelberg, Germany., Feng B; Precision Medicine, R&D, GSK, Waltham, Massachusetts. |
